Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

SHA:603538 Revenue

Ningbo Menovo Pharmaceutical had revenue of 521.17M CNY in the quarter ending June 30, 2026, with 30.02% growth. This brings the company's total for the last twelve months to 1.68B, up 16.80% year-over-year. In the year 2025, Ningbo Menovo Pharmaceutical had annual revenue of 1.50B with 9.49% growth. That makes Ningbo Menovo Pharmaceutical the 15,745th largest company in the world by revenue and 2,831st in China.

• Revenue (ttm): 1.68B
• Revenue Growth: +16.80%
• P/S Ratio: 4.34
• Revenue / Employee: 710.81K
• Employees: 2,370
• Market Cap: 7.31B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Intermediates and Raw Materials 769.00M 51.6%
• Preparations 611.90M 41.0%
• CDMO 84.10M 5.6%
• Trade 26.08M 1.7%

By Geography

Chart

• Overseas 1.02B 68.1%
• China 475.28M 31.9%

Fiscal year ended Dec 31, 2025 See the full SHA:603538 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.50B	130.27M	9.49%
Dec 31, 2024	1.37B	156.36M	12.85%
Dec 31, 2023	1.22B	-240.48M	-16.51%
Dec 31, 2022	1.46B	198.83M	15.80%
Dec 31, 2021	1.26B	64.77M	5.43%

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 18, 2026

Data Sources Report a data error